Misplaced Pages

Vasodilation

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Vasorelaxation) Widening of blood vessels
This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Vasodilation" – news · newspapers · books · scholar · JSTOR (March 2021)

Normal blood vessel (left) vs. vasodilation (right)

Vasodilation, also known as vasorelaxation, is the widening of blood vessels. It results from relaxation of smooth muscle cells within the vessel walls, in particular in the large veins, large arteries, and smaller arterioles. Blood vessel walls are composed of endothelial tissue and a basal membrane lining the lumen of the vessel, concentric smooth muscle layers on top of endothelial tissue, and an adventitia over the smooth muscle layers. Relaxation of the smooth muscle layer allows the blood vessel to dilate, as it is held in a semi-constricted state by sympathetic nervous system activity. Vasodilation is the opposite of vasoconstriction, which is the narrowing of blood vessels.

When blood vessels dilate, the flow of blood is increased due to a decrease in vascular resistance and increase in cardiac output. Vascular resistance is the amount of force circulating blood must overcome in order to allow perfusion of body tissues. Narrow vessels create more vascular resistance, while dilated vessels decrease vascular resistance. Vasodilation acts to increase cardiac output by decreasing afterload, −one of the four determinants of cardiac output.

By expanding available area for blood to circulate, vasodilation decreases blood pressure. The response may be intrinsic (due to local processes in the surrounding tissue) or extrinsic (due to hormones or the nervous system). In addition, the response may be localized to a specific organ (depending on the metabolic needs of a particular tissue, as during strenuous exercise), or it may be systemic (seen throughout the entire systemic circulation).

Endogenous substances and drugs that cause vasodilation are termed vasodilators. Many of these substances are neurotransmitters released by perivascular nerves of the autonomic nervous system Baroreceptors sense blood pressure and allow adaptation via the mechanisms of vasoconstriction or vasodilation to maintain homeostasis.

Function

The primary function of vasodilation is to increase blood flow in the body to tissues that need it most. This is often in response to a localized need for oxygen but can occur when the tissue in question is not receiving enough glucose, lipids, or other nutrients. Vasodilation, both localized and systemic, also facilitates immune response. Localized tissues have multiple ways to increase blood flow, including releasing vasodilators, primarily adenosine, into the local interstitial fluid, which diffuses to capillary beds, provoking local vasodilation. Some physiologists have suggested that it is the lack of oxygen itself that causes capillary beds to vasodilate by the smooth muscle hypoxia of the vessels in the region. This latter hypothesis is posited due to the presence of precapillary sphincters in capillary beds. These approaches to the mechanism of vasodilation have not been found to be mutually exclusive.

Immune system

Vasodilation plays a major role in immune system function. Wider blood vessels allow more blood containing immune cells and proteins to reach the infection site. Vasodilation occurs as part of the process of inflammation, which is caused by several factors including presence of a pathogen, injury to tissues or blood vessels, and immune complexes. In severe cases, inflammation can lead to sepsis or distributive shock. Vasodilation is also a major component of anaphylaxis.

Inflammation causes not only vasodilation but also causes increased vascular permeability, allowing neutrophils, complement proteins, and antibodies to reach the site of infection or damage. Elevated vascular permeability can allow excess fluid to leave blood vessels and collect in tissues resulting in edema; vasodilation prevents blood vessels from constricting to adapt to reduced volume in the vessels, causing low blood pressure and septic shock.

In the case of inflammation, vasodilation is caused by cytokines. Interferon gamma, TNF-a, interleukin 1 beta, and interleukin 12 are a few examples of some inflammatory cytokines produced by immune cells such as natural killer cells, B cells, T cells, mast cells and macrophages. Anti-inflammatory cytokines that regulate inflammation and help prevent negative results such as septic shock are also produced by these immune cells. Vasodilation and increased vascular permeability also allow immune effector cells to leave blood vessels and follow chemoattractants to the infection site via a process called leukocyte extravasation. Vasodilation allows the same volume of blood to move more slowly according to the flow rate equation Q = Av, where Q represents flow rate, A represents cross-sectional area, and v represents velocity. Immune effector cells can more easily attach to selectins expressed on endothelial cells when blood is flowing slowly, enabling these cells to exit the blood vessel via diapedesis.

Anaphylaxis is a severe allergic reaction characterized by elevated vascular permeability, systemic vasodilation, gastrointestinal dysfunction, and respiratory dysfunction. Anaphylatoxins, specifically complement proteins C3a and C5a, bind to receptors on mast cells and basophils causing degranulation. Granules in these cells contain histamine, platelet-activating factor, and other compounds causing clinical manifestation of anaphylaxis- including systemic vasodilation causing dangerously low blood pressure. Immunoglobulin E, an antibody produced by plasma cells, also binds to receptors on mast cells and basophils causing degranulation.

Mechanism

A basic understanding of cardiac output, vascular resistance, and blood pressure is necessary to understand the causes and impacts of vasodilation. Cardiac output is defined as the amount of blood pumped through the heart over 1 minute, in units of liters per minute, equal to heart rate multiplied by stroke volume. It is directly related to heart rate, myocardial contractility, and preload, and inversely related with afterload. Elevated vascular resistance due to constricted blood vessels causes in increase in afterload, the amount of force against which the heart must contract. Vasodilation therefore decreases vascular resistance, which decreases afterload, elevating cardiac output and allowing perfusion of tissues. Blood pressure measures how much pressure blood exerts on blood vessel walls; systolic blood pressure measures pressure while the heart contracts (systole), and diastolic blood pressure reflects pressure between contractions (diastole). Mean arterial pressure (MAP)is a weighted average of systolic and diastolic blood pressures, and is a better measurement of perfusion over the duration of the cardiac cycle. Vasodilation works to decrease vascular resistance and blood pressure through relaxation of smooth muscle cells in the tunica media layer of large arteries and smaller arterioles. When vasodilation causes systolic blood pressure to fall below 90 mmHg, circulatory shock is observed.

Vascular resistance depends on several factors, including the length of the vessel, the viscosity of blood (determined by hematocrit) and the diameter of the blood vessel. The latter is the most important variable in determining resistance, with the vascular resistance changing by the fourth power of the radius. An increase in either of these physiological components (cardiac output or vascular resistance) causes a rise in MAP. Arterioles create the most vascular resistance of any blood vessel type, as they are very narrow and possess concentric layers of smooth muscle unlike venules and capillaries.

Vasodilation occurs in superficial blood vessels of warm-blooded animals when their ambient environment is hot; this process diverts the flow of heated blood to the skin of the animal, where heat can be more easily released to the environment. The opposite physiological process is vasoconstriction. These processes are naturally modulated by local paracrine agents from endothelial cells (e.g., nitric oxide, bradykinin, potassium ions, and adenosine), and by the autonomic nervous system and the adrenal glands, both of which secrete catecholamines, such as norepinephrine and epinephrine, respectively.

Smooth muscle physiology

The tunica media of the walls of arteries, arterioles, and veins is composed of smooth muscle and causes vasodilation and vasoconstriction. Contraction of smooth muscle cells causes vasoconstriction, and relaxation of smooth muscle causes vasodilation. Smooth muscle is innervated by the autonomic nervous system and is non-striated (does not contain sarcomeres). Contraction is dependent on concentrations of Ca in the cytosol, either via Ca,Mg-ATPase from the sarcoplasmic reticulum or voltage-gated calcium channels from the extracellular matrix. Calcium ions bind with calmodulin, activating myosin light-chain kinase which phosphorylates the myosin light-chain. Phosphorylated light-chain myosin interacts with actin filaments forming a cross-bridge, allowing muscle contraction causing vasoconstriction. Vasodilation is caused by myosin-light-chain phosphatase, which dephosphorylates the myosin light chain causing muscle relaxation. Smooth muscle cells can remain contracted without use of ATP due to action of the myosin-binding subunit of myosin light-chain phosphatase. Phosphorylation of this subunit by Rho-kinase prevents it from binding to and dephosphorylating the myosin light-chain, allowing the cell to remain contracted.

Vasodilation is the result of relaxation in smooth muscle surrounding the blood vessels. This relaxation, in turn, relies on removing the stimulus for contraction, which depends on intracellular calcium ion concentrations and is tightly linked with phosphorylation of the light chain of the contractile protein myosin. Thus, vasodilation works mainly either by lowering intracellular calcium concentration or by dephosphorylation (really substitution of ATP for ADP) of myosin. Dephosphorylation by myosin light-chain phosphatase and induction of calcium symporters and antiporters that pump calcium ions out of the intracellular compartment both contribute to smooth muscle cell relaxation and therefore vasodilation. This is accomplished through reuptake of ions into the sarcoplasmic reticulum via exchangers and expulsion across the plasma membrane. There are three main intracellular stimuli that can result in the vasodilation of blood vessels. The specific mechanisms to accomplish these effects vary from vasodilator to vasodilator.

Class Description Example
Hyperpolarization-mediated (Calcium channel blocker) Changes in the resting membrane potential of the cell affects the level of intracellular calcium through modulation of voltage-sensitive calcium channels in the plasma membrane. adenosine
cAMP-mediated Adrenergic stimulation results in elevated levels of cAMP and protein kinase A, which results in increasing calcium removal from the cytoplasm. prostacyclin
cGMP-mediated (Nitrovasodilator) Through stimulation of protein kinase G. nitric oxide

PDE5 inhibitors and potassium channel openers can also have similar results.

Compounds that mediate the above mechanisms may be grouped as endogenous and exogenous.

Causes

Endogenous

Vasodilators Receptor
(↑ = opens. ↓ = closes)
On vascular smooth muscle cells if not otherwise specified
Transduction
(↑ = increases. ↓ = decreases)
EDHF ? hyperpolarization → ↓VDCC → ↓intracellular Ca
PKG activity →
  • phosphorylation of MLCK → ↓MLCK activity → dephosphorylation of MLC
  • SERCA → ↓intracellular Ca
NO receptor on endothelium endothelin synthesis
epinephrine (adrenaline) (Vasoconstrictor) β-2 adrenergic receptor Gs activity → ↑AC activity → ↑cAMP → ↑PKA activity → phosphorylation of MLCK → ↓MLCK activity → dephosphorylation of MLC
histamine histamine H2 receptor
prostacyclin IP receptor
prostaglandin D2 DP receptor
prostaglandin E2 EP receptor
VIP VIP receptor Gs activity → ↑AC activity → ↑cAMP → ↑PKA activity →
(extracellular) adenosine A1, A2a and A2b adenosine receptors ATP-sensitive K channel → hyperpolarization → close VDCC → ↓intracellular Ca
  • (extracellular) ATP
  • (extracellular) ADP
P2Y receptor activate Gq → ↑PLC activity → ↑intracellular Ca → ↑NOS activity → ↑NO → (see nitric oxide)
L-arginine imidazoline and α-2 receptor? Gi → ↓cAMP → activation of Na/K-ATPase → ↓intracellular Na → ↑Na/Ca exchanger activity → ↓intracellular Ca
bradykinin bradykinin receptor
substance P
niacin (as nicotinic acid only)
platelet-activating factor (PAF)
CO2 - interstitial pH → ?
interstitial lactic acid (probably) -
muscle work -
various receptors on endothelium endothelin synthesis

The vasodilating action of activation of beta-2 receptors (such as by adrenaline) appears to be endothelium-independent.

Autonomic nervous system control

As referenced in the explanation of smooth muscle physiology, smooth muscle within the tunica media is innervated by the autonomic nervous system. The autonomic nervous system (ANS) controls essential involuntary body functions and originates as nerves leaving the brain stem or spinal cord; it contains both sensor and motor nerves. The two divisions of the ANS, the sympathetic nervous system (SNS) and the parasympathetic nervous system (PSNS), impact blood vessels differently. Traditionally we understand that these two divisions work against each other, the SNS producing "fight or flight" and the PSNS producing "rest and digest", but in the case of vascular innervation this line becomes blurred ANS nerves do not directly innervate the vasculature via synapses with muscle cells; instead, they release neurotransmitters that reach target cells and effect smooth muscle contraction or relaxation. Physical characteristics of the SNS and PSNS cause the SNS to have a prolonged, systemic impact on blood vessels, while the PSNS causes short-lived, localized change. SNS stimulation causes a base level of vasoconstriction often referred to as basal neural tone, maintaining blood pressure. Often vasodilation is simply the result of insufficient neurotransmitter to maintain basal neural tone, without the presence of a compound directly causing vasodilation.

Neurotransmitters can act by binding directly to smooth muscle cells or by binding to endothelial cells mediating the effects of the neurotransmitter. Below is a table summarizing major neurotransmitters involved in regulation of the vasculature.

Neurotransmitter Sympathetic or Parasympathetic Target Cells and Receptors Impact on Vasculature
norepinephrine (NE) sympathetic (mostly) adrenergic receptors α1, α2, β1, β2

α1- smooth muscle α2- endothelial β1, β2- smooth muscle

α1- increase concentration calcium ions, vasoconstricton

α2- inhibit cAMP, release NO, vasodilation β1, β2- possible vasodilation

Acetylcholine (Ach) parasympathetic nicotonic Ach receptors (nAchRs)

muscanaric Ach receptors (mAchRs) - on both endothelial and smooth muscle cells

nAchRs- modulate cytokines, counteract inflammation

mAchRs- endothelial M3 AchR release NO, vasodlation smooth muscle M2 and M3 AchRs reduce release NO, vasoconstriction Note: Ach is quickly broken down, diffused, or undergoes reuptake, impacts are brief and localized

Adenosine triphosphate (ATP) sympathetic purinergic receptors on smooth muscle and endothelial cells smooth muscle- increase calcium ion concentration, vasoconstriction

endothelium- possible role as mediator of hyperpolarization of smooth muscle cells co-released with norepinephrine

Neuropeptide Y (NPY) sympathetic receptors on endothelial cells causes vasoconstriction when co-released with norepinephrine
CGRP ? CGRP1, CGRP2 receptors in endothelium vasodilation, role in vascular dysfunction if levels are abnormal

Also worthy of mention when discussing neural control of vasodilation is the renin-angiotensin-aldosterone system, or RAAS. The kidneys retain water by reabsorbing sodium ions, or eliminate water by eliminating sodium ions. Sympathetic nervous system activity, reduced blood volume or reduced arterial pressure trigger β-adrenergic receptors in select kidney cells to release renin, which converts facilitates formation of angiotensin II from its substrate angiotensin. Angiotensin II triggers adrenal glands to secrete aldosterone, a potent vasoconstrictor.

Epinephrine, either exogenous or endogenous, is another vasoconstrictor released by the adrenal glands in response to stress. It binds to α and β adrenergic receptors like norepinephrine, causing vasodilation and vasoconstriction in different body parts to redistribute circulation to critical areas.

Cold-induced

Cold-induced vasodilation (CIVD) occurs after cold exposure, possibly to reduce the risk of injury. It can take place in several locations in the human body but is observed most often in the extremities. The fingers are especially common because they are exposed most often.

When the fingers are exposed to cold, vasoconstriction occurs first to reduce heat loss, resulting in strong cooling of the fingers. Approximately five to ten minutes after the start of the cold exposure of the hand, the blood vessels in the finger tips will suddenly vasodilate. This is probably caused by a sudden decrease in the release of neurotransmitters from the sympathetic nerves to the muscular coat of the arteriovenous anastomoses due to local cold. The CIVD increases blood flow and subsequently the temperature of the fingers. This can be painful and is sometimes known as the 'hot aches' which can be painful enough to bring on vomiting.

A new phase of vasoconstriction follows the vasodilation, after which the process repeats itself. This is called the Hunting reaction. Experiments have shown that three other vascular responses to immersion of the finger in cold water are possible: a continuous state of vasoconstriction; slow, steady, and continuous rewarming; and a proportional control form in which the blood vessel diameter remains constant after an initial phase of vasoconstriction. However, the vast majority of responses can be classified as the Hunting reaction.

Miscellaneous

This section needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Vasodilation" – news · newspapers · books · scholar · JSTOR (March 2022)

Treatment

Direct vasodilation drugs

These drugs can keep vessels staying opened or help vessels refrain from being narrowed.

Alpha-2A adrenergic receptor agonists

Drugs that appear to work by activating the α2A receptors in the brain thereby decreasing sympathetic nervous system activity.

According to American Heart Association, Alpha-methyldopa may cause Orthostatic syncope as it exerts a greater blood pressure lowering effect when one is standing upright which may lead to feeling weak or fainting if the blood pressure has been lowered too far. Methyldopa's prominent side effects include drowsiness or sluggishness, dryness of the mouth, fever or anemia. Additionally to these, male patients may experience impotence.
Clonidine, guanabenz or guanfacine may give rise to severe dryness of the mouth, constipation or drowsiness. Abrupt cessation taking may raise blood pressure quickly to dangerously high levels.

Blood vessel muscle relaxants

Directly relax the muscle in the walls of the blood vessels (especially the arterioles), allowing the vessel to dilate (widen).

Hydralazine may cause headaches, swelling around the eyes, heart palpitations or aches and pains in the joints. In clinical setting, hydralazine is not usually used alone.
Minoxidil is a potent direct vasodilator used only in resistant severe high blood pressure or when kidney failure is present. Noted adverse effects comprise fluid retention (marked weight gain) and excessive hair growth.

Therapeutic applications

Vasodilators are used to treat conditions such as hypertension, wherein the patient has an abnormally high blood pressure, as well as angina, congestive heart failure, and erectile dysfunction, and where maintaining a lower blood pressure reduces the patient's risk of developing other cardiac problems. Flushing may be a physiological response to vasodilators. Some phosphodiesterase inhibitors such as sildenafil, vardenafil and tadalafil, work to increase blood flow in the penis through vasodilation. They may also be used to treat pulmonary arterial hypertension (PAH).

See also

References

  1. ^ "Definition of Vasodilation". MedicineNet.com. 27 April 2011. Archived from the original on 5 January 2012. Retrieved 13 January 2012.
  2. ^ Thomas GD (March 2011). "Neural control of the circulation". Advances in Physiology Education. 35 (1): 28–32. doi:10.1152/advan.00114.2010. PMID 21385998.
  3. ^ Tucker WD, Arora Y, Mahajan K (2024). "Anatomy, Blood Vessels". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29262226. Retrieved 22 March 2024.
  4. ^ Vincent JL (22 August 2008). "Understanding cardiac output". Critical Care. 12 (4): 174. doi:10.1186/cc6975. PMC 2575587. PMID 18771592.
  5. Ramanlal R, Gupta V (2024). "Physiology, Vasodilation". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32491494. Retrieved 22 March 2024.
  6. ^ Sheng Y, Zhu L (2018). "The crosstalk between autonomic nervous system and blood vessels". International Journal of Physiology, Pathophysiology and Pharmacology. 10 (1): 17–28. PMC 5871626. PMID 29593847.
  7. ^ Sprague AH, Khalil RA (September 2009). "Inflammatory cytokines in vascular dysfunction and vascular disease". Biochemical Pharmacology. 78 (6): 539–52. doi:10.1016/j.bcp.2009.04.029. PMC 2730638. PMID 19413999.
  8. Costa F, Biaggioni I (May 1998). "Role of nitric oxide in adenosine-induced vasodilation in humans". Hypertension. 31 (5): 1061–1064. doi:10.1161/01.HYP.31.5.1061. PMID 9576114.
  9. Sato A, Terata K, Miura H, Toyama K, Loberiza FR, Hatoum OA, et al. (April 2005). "Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease". American Journal of Physiology. Heart and Circulatory Physiology. 288 (4): H1633–H1640. doi:10.1152/ajpheart.00575.2004. PMID 15772334. S2CID 71178.
  10. Guyton A, Hall J (2006). "Chapter 17: Local and Humoral Control of Blood Flow by the Tissues". In Gruliow R (ed.). Textbook of Medical Physiology (Book) (11th ed.). Philadelphia, Pennsylvania: Elsevier Inc. pp. 196–197. ISBN 978-0-7216-0240-0.
  11. ^ Vincent JL, De Backer D (October 2013). Finfer SR, Vincent JL (eds.). "Circulatory shock". The New England Journal of Medicine. 369 (18): 1726–1734. doi:10.1056/NEJMra1208943. PMID 24171518.
  12. ^ Pałgan K (August 2023). "Mast Cells and Basophils in IgE-Independent Anaphylaxis". International Journal of Molecular Sciences. 24 (16): 12802. doi:10.3390/ijms241612802. PMC 10454702. PMID 37628983.
  13. ^ Nourshargh S, Alon R (November 2014). "Leukocyte migration into inflamed tissues". Immunity. 41 (5): 694–707. doi:10.1016/j.immuni.2014.10.008. PMID 25517612.
  14. "What is volume flow rate? (article) | Fluids". Khan Academy. Retrieved 23 March 2024.
  15. Nguyen SM, Rupprecht CP, Haque A, Pattanaik D, Yusin J, Krishnaswamy G (July 2021). "Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond". International Journal of Molecular Sciences. 22 (15): 7785. doi:10.3390/ijms22157785. PMC 8346007. PMID 34360549.
  16. DeMers D, Wachs D (2024). "Physiology, Mean Arterial Pressure". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30855814. Retrieved 23 March 2024.
  17. ^ Klablunde RE (29 April 2008). "Therapeutic Uses of Vasodilators". CVPharmacology. Archived from the original on 16 December 2008. Retrieved 3 December 2013.
  18. Trammel JE, Sapra A (2024). "Physiology, Systemic Vascular Resistance". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32310535. Retrieved 23 March 2024.
  19. Charkoudian N (October 2010). "Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans". Journal of Applied Physiology. 109 (4). American Physiological Society: 1221–1228. doi:10.1152/japplphysiol.00298.2010. PMC 2963327. PMID 20448028.
  20. Johnson JM, Kellogg DL (October 2010). "Local thermal control of the human cutaneous circulation". Journal of Applied Physiology. 109 (4). American Physiological Society: 1229–1238. doi:10.1152/japplphysiol.00407.2010. PMC 2963328. PMID 20522732.
  21. ^ Webb RC (December 2003). "Smooth muscle contraction and relaxation". Advances in Physiology Education. 27 (1–4): 201–206. doi:10.1152/advan.00025.2003. PMID 14627618.
  22. Webb RC (December 2003). "Smooth muscle contraction and relaxation". Advances in Physiology Education. 27 (1–4): 201–206. doi:10.1152/advan.00025.2003. PMID 14627618. S2CID 14267377.
  23. ^ Unless else specified in box, then ref is: Boron WF (2005). Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders. ISBN 978-1-4160-2328-9. Page 479
  24. ^ Flower R, Rang HP, Dale MM, Ritter JS (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 978-0-443-06911-6.
  25. Kurihara K, Nakanishi N, Ueha T (November 2000). "Regulation of Na(+)-K(+)-ATPase by cAMP-dependent protein kinase anchored on membrane via its anchoring protein". American Journal of Physiology. Cell Physiology. 279 (5): C1516–C1527. doi:10.1152/ajpcell.2000.279.5.c1516. PMID 11029299. S2CID 8699034.
  26. Modin A, Björne H, Herulf M, Alving K, Weitzberg E, Lundberg JO (January 2001). "Nitrite-derived nitric oxide: a possible mediator of 'acidic-metabolic' vasodilation". Acta Physiologica Scandinavica. 171 (1): 9–16. doi:10.1046/j.1365-201X.2001.00771.x. PMID 11350258.
  27. Schindler C, Dobrev D, Grossmann M, Francke K, Pittrow D, Kirch W (January 2004). "Mechanisms of beta-adrenergic receptor-mediated venodilation in humans". Clinical Pharmacology and Therapeutics. 75 (1): 49–59. doi:10.1016/j.clpt.2003.09.009. PMID 14749691. S2CID 97773072.
  28. ^ Navar LG (July 2014). "Physiology: hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system". Journal of the American Society of Hypertension. 8 (7): 519–24. doi:10.1016/j.jash.2014.05.014. PMC 4115246. PMID 25064774.
  29. Daanen HA (June 2003). "Finger cold-induced vasodilation: a review". European Journal of Applied Physiology. 89 (5): 411–426. doi:10.1007/s00421-003-0818-2. PMID 12712346. S2CID 22077172.
  30. Hahad O, Kröller-Schön S, Daiber A, Münzel T (April 2019). "The Cardiovascular Effects of Noise". Deutsches Ärzteblatt International. 116 (14): 245–250. doi:10.3238/arztebl.2019.0245. PMC 6541745. PMID 31092312.
  31. Guieu R, Deharo JC, Maille B, Crotti L, Torresani E, Brignole M, et al. (May 2020). "Adenosine and the Cardiovascular System: The Good and the Bad". Journal of Clinical Medicine. 9 (5): 1366. doi:10.3390/jcm9051366. PMC 7290927. PMID 32384746.
  32. Nachawati D, Patel JB (2024). "Alpha-Blockers". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32310526. Retrieved 24 March 2024.
  33. Song W, Wang H, Wu Q (September 2015). "Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)". Gene. 569 (1): 1–6. doi:10.1016/j.gene.2015.06.029. PMC 4496260. PMID 26074089.
  34. Fuchs FD (May 2005). "Vascular effects of alcoholic beverages: is it only alcohol that matters?". Hypertension. 45 (5): 851–852. doi:10.1161/01.HYP.0000164627.01274.ec. PMID 15837832.
  35. Abukhodair AW, Abukhudair W, Alqarni MS (December 2021). "The Effects of L-Arginine in Hypertensive Patients: A Literature Review". Cureus. 13 (12): e20485. doi:10.7759/cureus.20485. PMC 8761475. PMID 35070535.
  36. Figueroa A, Wong A, Jaime SJ, Gonzales JU (January 2017). "Influence of L-citrulline and watermelon supplementation on vascular function and exercise performance". Current Opinion in Clinical Nutrition and Metabolic Care. 20 (1). Ovid Technologies (Wolters Kluwer Health): 92–98. doi:10.1097/mco.0000000000000340. PMID 27749691. S2CID 3493542.
  37. Kim KH, Kerndt CC, Adnan G, Schaller DJ (2024). "Nitroglycerin". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 29494004. Retrieved 24 March 2024.
  38. Balasubramanian S, Chowdhury YS (2024). "Isosorbide". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32491771. Retrieved 24 March 2024.
  39. Schuhmacher S, Wenzel P, Schulz E, Oelze M, Mang C, Kamuf J, et al. (April 2010). "Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1". Hypertension. 55 (4): 897–904. doi:10.1161/HYPERTENSIONAHA.109.149542. PMC 3080599. PMID 20157049.
  40. Holme MR, Sharman T (2024). "Sodium Nitroprusside". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32491419. Retrieved 24 March 2024.
  41. Shawish MI, Ben-Eltriki M, Wright JM (December 2019). "Effect of phosphodiesterase 5 inhibitors on blood pressure". Cochrane Database of Systematic Reviews. 12 (12): CD013507. doi:10.1002/14651858.CD013507. PMC 6914385.
  42. Latif Z, Garg N (June 2020). "The Impact of Marijuana on the Cardiovascular System: A Review of the Most Common Cardiovascular Events Associated with Marijuana Use". Journal of Clinical Medicine. 9 (6): 1925. doi:10.3390/jcm9061925. PMC 7355963. PMID 32575540.
  43. Martínez-Pinilla E, Oñatibia-Astibia A, Franco R (2015). "The relevance of theobromine for the beneficial effects of cocoa consumption". Frontiers in Pharmacology. 6: 30. doi:10.3389/fphar.2015.00030. PMC 4335269. PMID 25750625.
  44. Sica DA (May 2004). "Minoxidil: an underused vasodilator for resistant or severe hypertension". Journal of Clinical Hypertension. 6 (5): 283–287. doi:10.1111/j.1524-6175.2004.03585.x. PMC 8109604. PMID 15133413.
  45. Fusi F, Manetti F, Durante M, Sgaragli G, Saponara S (January 2016). "The vasodilator papaverine stimulates L-type Ca(2+) current in rat tail artery myocytes via a PKA-dependent mechanism". Vascular Pharmacology. 76: 53–61. doi:10.1016/j.vph.2015.11.041. PMID 26586313.
  46. Somani YB, Pawelczyk JA, De Souza MJ, Kris-Etherton PM, Proctor DN (August 2019). "Aging women and their endothelium: probing the relative role of estrogen on vasodilator function". American Journal of Physiology. Heart and Circulatory Physiology. 317 (2): H395–H404. doi:10.1152/ajpheart.00430.2018. PMC 6732482. PMID 31173499.
  47. ^ "Types of Blood Pressure Medications". www.heart.org. 31 October 2017. Archived from the original on 8 January 2019. Retrieved 2 May 2019.
  48. "Guanfacine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 18 March 2019.
Scholia has a topic profile for Vasodilation.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System
gastrointestinal tract
/ metabolism (A)
blood and blood
forming organs (B)
cardiovascular
system
(C)
skin (D)
genitourinary
system
(G)
endocrine
system
(H)
infections and
infestations (J, P, QI)
malignant disease
(L01–L02)
immune disease
(L03–L04)
muscles, bones,
and joints (M)
brain and
nervous system (N)
respiratory
system
(R)
sensory organs (S)
other ATC (V)
Vasodilators used in cardiac diseases (C01D)
Nitrovasodilators
Quinolone vasodilators
Others
Nonsympatholytic vasodilatory antihypertensives (C02)
Nitrovasodilator (arterioles and venules)
Hydrazinophthalazines (arterioles)
Potassium channel openers (arterioles)
Calcium channel blockers (arterioles)
Peripheral vasodilators (C04)
Phenylethanolamine derivatives
Alpha blockers
Niacin and derivatives
Purine derivatives
Ergot alkaloids
Other peripheral vasodilators
Physiology of the cardiovascular system
Heart
Cardiac output
Ultrasound
Heart rate
Conduction
Chamber pressure
Other
Vascular system/
hemodynamics
Blood flow
Blood pressure
Regulation of BP
Category: